IgGenix

04/16/2025

Still recruiting - last chance to be involved!

⚠️ LAST OPPORTUNITY! ⚠️

👉 Have you or your teen been diagnosed with a severe peanut allergy?
👉 Have you been to an Emergency Department with a severe allergic reaction/anaphylaxis to peanuts?
👉 Have you been prescribed an adrenaline autoinjector (EpiPen or Anapen)?

If so, you may be eligible for a new IgGenix study in Australia exploring whether an injectable antibody can help treat peanut allergy in teens and adults.

The study is recruiting participants at:
- Fiona Stanley Hospital (WA) - ages 15-55
- St Vincent's Hospital (NSW) - ages 18-55
- The Royal Melbourne Hospital (Victoria) - ages 18 - 55
- Monash Health (Victoria) - ages 15-55

Find out more ➡️ iggenix.com.au

04/15/2025

Please visit https://www.nace.org.au/allergy-studies-directory/
To learn more

04/15/2025

Final opportunity to be involved in the study! Allergy 250K
Allergy & Anaphylaxis Australia

A phase 1, randomised, double-blind clinical study by IgGenix Australia Pty Ltd to evaluate the safety and tolerability of an injectable, allergen-specific antibody therapeutic IGNX001.

04/15/2025

Still recruiting - last chance!

Recruiting now!

👉 Have you or your teen been diagnosed wtih a severe peanut allergy?
👉 Have you been to an Emergency Department with a severe allergic reaction/anaphylaxis to peanuts?
👉 Have you been prescribed an adrenaline autoinjector (EpiPen or Anapen)?

If so, you may be eligible for a new IgGenix study in Australia exploring whether an injectable antibody can help treat peanut allergy in teens and adults.

The study is recruiting participants at:
- Fiona Stanley Hospital ('WA) - ages 15-55
- St Vincent's Hospital (NSW) - ages 18-55
- The Royal Melbourne Hospital (Victoria) - ages 18 - 55
- Monash Health (Victoria) - ages 15-55

Find out more ➡️ iggenix.com.au

11/19/2024

Fiona Stanley Hospital Consultant Clinical Immunologist, Dr Michael O’Sullivan, is leading a new study looking at an injectable, allergen-specific antibody medicine – IGNX001 – targeting the peanut protein to provide protection against an allergic reaction 🥜

Known as the 'ACCELERATE Peanut’ study, the trial will assess if IGNX001 can help ease allergic reactions that might happen after accidental peanut exposure.

This treatment has the potential to not only change the way peanut allergies are managed across the world, but offers those suffering a faster, more effective alternative to current therapies.

Phase 1 of the trial is now recruiting. To find more about the trial and participation, visit 👉 https://fsfhg.health.wa.gov.au

11/19/2024

Exciting news!

Fiona Stanley Hospital Consultant Clinical Immunologist, Dr Michael O’Sullivan, is leading a new study looking at an injectable, allergen-specific antibody medicine – IGNX001 – targeting the peanut protein to provide protection against an allergic reaction 🥜

Known as the 'ACCELERATE Peanut’ study, the trial will assess if IGNX001 can help ease allergic reactions that might happen after accidental peanut exposure.

This treatment has the potential to not only change the way peanut allergies are managed across the world, but offers those suffering a faster, more effective alternative to current therapies.

Phase 1 of the trial is now recruiting. To find more about the trial and participation, visit 👉 https://fsfhg.health.wa.gov.au/News/2024/11/13/Ronald-hoping-to-benefit-from-FSH-ACCELERATE-peanut-allergy-trial

11/08/2024

As fall arrives, so does the reality of seasonal allergies for millions, triggered by allergens like ragweed to mold. At IgGenix, we’re committed to doing more than managing symptoms. Our focus is on developing innovative treatments that target the root cause of environmental allergies, helping people breathe easier and live better every season. Learn about our work: https://iggenix.com/

10/26/2024

Our study for IGNX001 has reached an exciting milestone! I'm so proud of and our partners at the Allergy Centre of Excellence for the hard work to get us here...and this is only the beginning of our mission to change the face of allergic disease as we know it. Read more: https://bit.ly/3Yq9sRF

10/26/2024

impact millions worldwide—30-40% of the global population experiences conditions like food, drug, and environmental allergies. At IgGenix, we’re tackling these challenges head-on through research like the study, driven to find real solutions that will improve lives.